BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

335 related articles for article (PubMed ID: 25392014)

  • 1. Molecular pathophysiology of priapism: emerging targets.
    Anele UA; Morrison BF; Burnett AL
    Curr Drug Targets; 2015; 16(5):474-83. PubMed ID: 25392014
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Long-term oral phosphodiesterase 5 inhibitor therapy alleviates recurrent priapism.
    Burnett AL; Bivalacqua TJ; Champion HC; Musicki B
    Urology; 2006 May; 67(5):1043-8. PubMed ID: 16698365
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mechanisms underlying priapism in sickle cell disease: targeting and key innovations on the preclinical landscape.
    Musicki B; Burnett AL
    Expert Opin Ther Targets; 2020 May; 24(5):439-450. PubMed ID: 32191546
    [No Abstract]   [Full Text] [Related]  

  • 4. How I treat priapism.
    Anele UA; Le BV; Resar LM; Burnett AL
    Blood; 2015 Jun; 125(23):3551-8. PubMed ID: 25810489
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subacute Hemolysis in Sickle Cell Mice Causes Priapism Secondary to NO Imbalance and PDE5 Dysregulation.
    Sopko NA; Matsui H; Hannan JL; Berkowitz D; Champion HC; Hsu LL; Musicki B; Burnett AL; Bivalacqua TJ
    J Sex Med; 2015 Sep; 12(9):1878-85. PubMed ID: 26346631
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New insights into the pathophysiology of sickle cell disease-associated priapism.
    Bivalacqua TJ; Musicki B; Kutlu O; Burnett AL
    J Sex Med; 2012 Jan; 9(1):79-87. PubMed ID: 21554553
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular analysis of erection regulatory factors in sickle cell disease associated priapism in the human penis.
    Lagoda G; Sezen SF; Cabrini MR; Musicki B; Burnett AL
    J Urol; 2013 Feb; 189(2):762-8. PubMed ID: 22982429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Medical treatment of recurrent ischaemic priapism: a review of current molecular therapeutics and a new clinical management paradigm.
    Joice GA; Liu JL; Burnett AL
    BJU Int; 2021 May; 127(5):498-506. PubMed ID: 33606327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Potential risks of chronic sildenafil use for priapism in sickle cell disease.
    Lane A; Deveras R
    J Sex Med; 2011 Nov; 8(11):3193-5. PubMed ID: 21883942
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized controlled trial of sildenafil for preventing recurrent ischemic priapism in sickle cell disease.
    Burnett AL; Anele UA; Trueheart IN; Strouse JJ; Casella JF
    Am J Med; 2014 Jul; 127(7):664-8. PubMed ID: 24680796
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Molecular Profile of Priapism Associated with Low Nitric Oxide Bioavailability.
    La Favor JD; Fu Z; Venkatraman V; Bivalacqua TJ; Van Eyk JE; Burnett AL
    J Proteome Res; 2018 Mar; 17(3):1031-1040. PubMed ID: 29394072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Medical management of ischemic stuttering priapism: a contemporary review of the literature.
    Levey HR; Kutlu O; Bivalacqua TJ
    Asian J Androl; 2012 Jan; 14(1):156-63. PubMed ID: 22057380
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Insights of priapism mechanism and rationale treatment for recurrent priapism.
    Yuan J; Desouza R; Westney OL; Wang R
    Asian J Androl; 2008 Jan; 10(1):88-101. PubMed ID: 18087648
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Priapism and sickle-cell anemia: diagnosis and nonsurgical therapy.
    Broderick GA
    J Sex Med; 2012 Jan; 9(1):88-103. PubMed ID: 21699659
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Sustained nitric oxide (NO)-releasing compound reverses dysregulated NO signal transduction in priapism.
    Lagoda G; Sezen SF; Hurt KJ; Cabrini MR; Mohanty DK; Burnett AL
    FASEB J; 2014 Jan; 28(1):76-84. PubMed ID: 24076963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevention of Ischemic Priapism in Sickle Cell Disease: Sildenafil: Commentary on: Randomized Controlled Trial of Sildenafil for Preventing Recurrent Ischemic Priapism in Sickle Cell Disease.
    Shakeri A; Van Asseldonk B; Elterman DS
    Urology; 2015 Dec; 86(6):1055-6. PubMed ID: 26431892
    [No Abstract]   [Full Text] [Related]  

  • 17. Hydroxyurea therapy for priapism prevention and erectile function recovery in sickle cell disease: a case report and review of the literature.
    Anele UA; Mack AK; Resar LMS; Burnett AL
    Int Urol Nephrol; 2014 Sep; 46(9):1733-1736. PubMed ID: 24824148
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Adenosine signaling: good or bad in erectile function?
    Wen J; Xia Y
    Arterioscler Thromb Vasc Biol; 2012 Apr; 32(4):845-50. PubMed ID: 22423035
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Stuttering priapism: insights into pathogenesis and management.
    Morrison BF; Burnett AL
    Curr Urol Rep; 2012 Aug; 13(4):268-76. PubMed ID: 22648304
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Priapism pathophysiology: clues to prevention.
    Burnett AL
    Int J Impot Res; 2003 Oct; 15 Suppl 5():S80-5. PubMed ID: 14551582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.